Companies
Abogen licenses mRNA T-cell engager to Novartis for $575M upfront
Abogen: $575M upfront and up to about $7.2B milestones if all options exercised for ABO2203 worldwide rights; deal still subject to regulatory clearances.
Search stocks, ETFs and companies
2 sourced reports attached to this file.
Verified identity
Start with the filing record
The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.
- Ticker
- NVS
- CIK
- 0001114448
- Exchange
- NYSE
- Universe updated
- 2026-08-22
Market price
Market price
Latest quoteOpens Google
TickerGrove coverage
Latest on NOVARTIS AG
Research foundation
Read the filing with the right frame
Company analysis
Revenue, EPS and guidance answer different earnings questions
Revenue is the top-line amount recognized from a company’s activities under its accounting policy.
Company analysis
The three financial statements describe one business from different angles
The income statement records revenue and expenses over a period.
Investing basics
Stocks, ETFs and indexes are different objects
A stock is an ownership interest in one company.